Synaptic and behavioral interactions of oseltamivir (Tamiflu) with neurostimulants

Human and Experimental Toxicology

Volumn 27, Issue 12, 2008, Pages 911-917

  Izumi, Y ^a,c   Tokuda, K ^a   O'Dell, K A ^a   Zorumski, C F ^a   Narahashi, T ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c WASHINGTON UNIVERSITY   (United States)

Author keywords

Avian influenza; Caffeine; Ephedrine; Long term depression; Oseltamivir; Tamiflu

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; ALCOHOL; CAFFEINE; EPHEDRINE; OSELTAMIVIR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; BRAIN SLICE; CELL FUNCTION; CONTROLLED STUDY; DRUG POTENTIATION; EX VIVO STUDY; HIPPOCAMPUS; LONG TERM DEPRESSION; MALE; MAZE TEST; NERVE CELL PLASTICITY; NERVE EXCITABILITY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIVIRAL AGENTS; BEHAVIOR, ANIMAL; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; DRUG INTERACTIONS; ENZYME INHIBITORS; EPHEDRINE; ETHANOL; EXCITATORY POSTSYNAPTIC POTENTIALS; HIPPOCAMPUS; LOCOMOTION; LONG-TERM SYNAPTIC DEPRESSION; MALE; NEURAMINIDASE; OSELTAMIVIR; RATS; RATS, SPRAGUE-DAWLEY; RISK ASSESSMENT; TIME FACTORS;

ANIMALIA; AVES;

EID: 62249089513     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1177/0960327109102367     Document Type: Article

References (39)

1. Abdel-Ghafar AN. Chotpitayasunondh T. Gao Z. Hayden FG. Nguyen DH. de Jong MD.. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 2008 ; 358: 261-273.
2. Cinatl J. Michaelis M. Doerr HW.. The threat of avian influenza A (H5N1). Part I: Epidemiologic concerns and virulence determinants. Med Microbiol Immunol 2007 ; 196: 181-190.
3. Crusat M. de Jong MD.. Neuraminidase inhibitors and their role in avian and pandemic influenza. Antivir Ther 2007 ; 12 (4 Pt B): 593-602.
4. Lowen AC. Palese P.. Influenza virus transmission: basic science and implications for the use of antiviral drugs during a pandemic. Infect Disord Drug Targets 2007 ; 7: 318-328.
5. Fuyuno I.. Tamiflu side effects come under scrutiny. Nature 2007 ; 446: 358-359.
6. Maxwell SR.. Tamiflu and neuropsychiatric disturbance in adolescents. BMJ 2007 ; 334: 1232-1233.
7. Blumentals WA. Song X.. The safety of oseltamivir in patients with influenza: analysis of healthcare claims data from six influenza seasons. Med Gen Med 2007 ; 9: 23.
8. Terada K. Kawai Y. Monju A. Wakabayashi T. Ouchi K.. Adolescent jump case in Japan associated with influenza but not oseltamivir. Pediatr Infect Dis J 2008 ; 27: 88-89.
9. http://www.fda.gov/medwatch/safety/2008/safety08.htm#Tamiflu
10. He G. Massarella J. Ward P.. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 1999 ; 37: 471-484.
11. Sweeny DJ. Lynch G. Bidgood AM. Lew W. Wang KY. Cundy KC.. Metabolism of the influenza neuraminidase inhibitor prodrug oseltamivir in the rat. Drug Metab Dispos 2000 ; 28: 737-741.
12. Crain SM. Shen KF.. Neuraminidase inhibitor, oseltamivir blocks GM1 ganglioside-regulated excitatory opioid receptor-mediated hyperalgesia, enhances opioid analgesia and attenuates tolerance in mice. Brain Res 2004 ; 995: 260-266.
13. Da Silva JS. Hasegawa T. Miyagi T. Dotti CG. Abad-Rodriguez J.. Asymmetric membrane ganglioside sialidase activity specifies axonal fate. Nat Neurosci 2005 ; 8: 606-615.
14. Rodriguez JA. Piddini E. Hasegawa T. Miyagi T. Dotti CG.. Plasma membrane ganglioside sialidase regulates axonal growth and regeneration in hippocampal neurons in culture. J Neurosci 2001 ; 21: 8387-8395.
15. Isaev D. Isaeva E. Shatskih T. Zhao Q. Smits NC. Shworak NW.. Role of extracellular sialic acid in regulation of neuronal and network excitability in the rat hippocampus. J Neurosci 2007 ; 27: 11587-11594.
16. Boyzo A. Ayala J. Gutiérrez R.. Hernández-RJ. Neuraminidase activity in different regions of the seizing epileptic and non-epileptic brain. Brain Res. 2003 ; 964: 211-217.
17. Izumi Y. Tokuda K.. O'dell, KA, Zorumski, CF, Narahashi, T. Neuroexcitatory actions of Tamiflu and its carboxylate metabolite. Neurosci Lett 2007 ; 426: 54-58.
18. Usami A. Sasaki T. Satoh N. Akiba T. Yokoshima S. Fukuyama T.. Oseltamivir enhances hippocampal network synchronization. J Pharmacol Sci 2008 ; 106: 659-662.
19. Wooltorton E.. Oseltamivir (Tamiflu) unsafe in infants under 1 year old. CMAJ 2004 ; 170: 336.
20. Morimoto K. Nakakariya M. Shirasaka Y. Kakinuma C. Fujita T. Tamai I.. Oseltamivir (Tamiflu) Efflux Transport at the Blood-Brain Barrier via P-Glycoprotein. Drug Metab Dispos 2008 ; 36: 6-9.
21. Ono H. Nagano Y. Matsunami N. Sugiyama S. Yamamoto S. Tanabe M.. Oseltamivir, an anti-influenza virus drug, produces hypothermia in mice. Biol Pharm Bull 2008 ; 31: 638-642.
22. Yoshino T. Nisijima K. Shioda K. Yui K. Kato S.. Oseltamivir (Tamiflu) increases dopamine levels in the rat medial prefrontal cortex. Neurosci Lett 2008 ; 438: 67-69.
23. Wada K. Price RK. Fukui S.. Reflecting adult drinking culture: prevalence of alcohol use and drinking situations among Japanese junior high school students in Japan. J Stud Alcohol 1998 ; 59: 381-386.
24. Stewart PA. Hayakawa EM. Carlen PL.. Ethanol and pentobarbital in combination increase blood-brain barrier permeability to horseradish peroxidase. Brain Res 1988 ; 443: 12-20.
25. Gallitano-Mendel A. Izumi Y. Tokuda K. Zorumski CF. Howell MP. Muglia LJ.. The immediate early gene early growth response gene 3 mediates adaptation to stress and novelty. Neuroscience 2007 ; 148: 633-643.
26. Izumi Y. Kitabayashi R. Funatsu M. Izumi M. Yuede C. Hartman RE.. A single day of ethanol exposure during development has persistent effects on bi-directional plasticity, N-methyl-D-aspartate receptor function and ethanol sensitivity. Neuroscience 2005 ; 136: 269-279.
27. Nakao K. Ikegaya Y. Yamada MK. Nishiyama N. Matsuki N.. Spatial performance correlates with long-term potentiation of the dentate gyrus but not of the CA1 region in rats with fimbria-fornix lesions. Neurosci Lett 2001 ; 307: 159-162.
28. Shuhama R. Del-Ben CM. Loureiro SR. Graeff FG.. Animal defense strategies and anxiety disorders. An Acad Bras Cienc 2007 ; 79: 97-109.
29. Blanchard RJ. Hebert MA. Ferrari PF. Palanza P. Figueira R. Blanchard DC.. Defensive behaviors in wild and laboratory (Swiss) mice: the mouse defense test battery. Physiol Behav 1998 ; 65: 201-209.
30. Gregory PJ.. Evaluation of the stimulant content of dietary supplements marketed as "ephedra-free". J Herb Pharmacother 2007 ; 7: 65-72.
31. Abourashed EA. El-Alfy AT. Khan IA. Walker L.. Ephedra in perspective-a current review. Phytother Res 2003 ; 17: 703-712.
32. Jacobs KM. Hirsch KA.. Psychiatric complications of Ma-huang. Psychosomatics 2000 ; 41: 58-62.
33. Doyle H. Kargin M.. Herbal stimulant containing ephedrine has also caused psychosis. BMJ 1996 ; 313: 756.
34. Haverkos HW. Amsel Z. Drotman DP.. Adverse virus-drug interactions. Rev Infect Dis 1991 ; 13: 697-704.
35. Levy M.. Role of viral infections in the induction of adverse drug reactions. Drug Saf 1997 ; 16: 1-8.
36. Ose A. Kusuhara H. Yamatsugu K. Kanai M. Shibasaki M. Fujita T.. P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier. Drug Metab Dispos 2008 ; 36: 427-434.
37. Jhee SS. Yen M. Ereshefsky L. Leibowitz M. Schulte M. Kaeser B.. Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteers. Antimicrob Agents Chemother 2008 ; 52: 3687-3693.
38. Li CY. Yu Q. Ye ZQ. Sun Y. He Q. Li XM.. A nonsynonymous SNP in human cytosolic sialidase in a small Asian population results in reduced enzyme activity: potential link with severe adverse reactions to oseltamivir. Cell Res 2007 ; 17: 357-362.
39. Long M.. Side effects of Tamiflu: clues from an Asian single nucleotide polymorphism. Cell Res 2007 ; 17: 309-310.